TY - JOUR
T1 - Deep brain stimulation of the human reward system for major depression - Rationale, outcomes and outlook
AU - Schlaepfer, Thomas E.
AU - Bewernick, Bettina H.
AU - Kayser, Sarah
AU - Hurlemann, Rene
AU - Coenen, Volker A.
N1 - Funding Information:
TES and VAC received partial funding for two investigator-initiated studies on DBS for major depression from Medtronic Inc. and the Hope for Depression Research Foundation (HDRF) and the Institute for Affective Neuroscience (ISAN). VAC is consultant for Medtronic Europe and occasionally received honoraria for talks. TS is chair of the project group, ‘Deep Brain Stimulation in Psychiatry: Guidance for Responsible Research and Application’, funded by the Volkswagen Foundation (Hanover, Germany). TS and BB are members of the working Group Neuromodulation of the German Research Foundation. RH was supported by a Starting Independent Researcher Grant (NEMO—Neuromodulation of Emotion) jointly provided by the Ministry of Innovation, Science, Research and Technology of the German State of North Rhine-Westphalia (MIWFT) and the University of Bonn.
PY - 2014/5
Y1 - 2014/5
N2 - Deep brain stimulation (DBS) as a putative approach for treatment-resistant depression (TRD) has now been researched for about a decade. Several uncontrolled studies - all in relatively small patient populations and different target regions - have shown clinically relevant antidepressant effects in about half of the patients and very recently, DBS to a key structure of the reward system, the medial forebrain bundle, has yielded promising results within few days of stimulation and at much lower stimulation intensities. On the downside, DBS procedures in regions are associated with surgical risks (eg, hemorrhage) and psychiatric complications (suicidal attenuation, hypomania) as well as high costs. This overview summarizes research on the mechanisms of brain networks with respect to psychiatric diseases and - as a novelty - extrapolates to the role of the reward system in DBS for patients with treatment-resistant depression. It further evaluates relevant methodological aspects of today's research in DBS for TRD. On the scientific side, the reward system has an important yet clearly under-recognized role in both neurobiology and treatment of depression. On the methodological side of DBS research in TRD, better animal models are clearly needed to explain clinical effects of DBS in TRD. Larger sample sizes, long-term follow-up and designs including blinded sham control are required to draw final conclusions on efficacy and side effects. Practical research issues cover study design, patient tracking, and the discussion of meaningful secondary outcome measures.
AB - Deep brain stimulation (DBS) as a putative approach for treatment-resistant depression (TRD) has now been researched for about a decade. Several uncontrolled studies - all in relatively small patient populations and different target regions - have shown clinically relevant antidepressant effects in about half of the patients and very recently, DBS to a key structure of the reward system, the medial forebrain bundle, has yielded promising results within few days of stimulation and at much lower stimulation intensities. On the downside, DBS procedures in regions are associated with surgical risks (eg, hemorrhage) and psychiatric complications (suicidal attenuation, hypomania) as well as high costs. This overview summarizes research on the mechanisms of brain networks with respect to psychiatric diseases and - as a novelty - extrapolates to the role of the reward system in DBS for patients with treatment-resistant depression. It further evaluates relevant methodological aspects of today's research in DBS for TRD. On the scientific side, the reward system has an important yet clearly under-recognized role in both neurobiology and treatment of depression. On the methodological side of DBS research in TRD, better animal models are clearly needed to explain clinical effects of DBS in TRD. Larger sample sizes, long-term follow-up and designs including blinded sham control are required to draw final conclusions on efficacy and side effects. Practical research issues cover study design, patient tracking, and the discussion of meaningful secondary outcome measures.
KW - deep brain stimulation
KW - major depression
KW - medial forebrain bundle
KW - neuromodulation
KW - nucleus accumbens
KW - reward system
UR - http://www.scopus.com/inward/record.url?scp=84900825260&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84900825260&partnerID=8YFLogxK
U2 - 10.1038/npp.2014.28
DO - 10.1038/npp.2014.28
M3 - Review article
C2 - 24513970
AN - SCOPUS:84900825260
VL - 39
SP - 1303
EP - 1314
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
SN - 0893-133X
IS - 6
ER -